Question-and-Answer Session
Operator
(Operator Instructions) Please hold while we compile a list of questions. Your first question comes from the line of Eric Schmidt from Cowen & Company. Please proceed.
Eric Schmidt – Cowen & Company
Can I ask a question on ACAPODENE not related to either of the two clinical trials? You had mentioned possibly starting additional studies on ACAPODENE and ADT therapy to try and look at the drug’s affect on gynecomastia and hot flashes, things like that. Are those still at least in the back of your mind or where do we stand?
Mitchell S. Steiner, M.D.
That’s a great question and let’s see if I can frame it this way, one of the things that we’re trying to do with ADT is position ourselves as a multiple side effects treatment for prostate cancer. To that end, we’ve already shown that we have an effect on bone loss, we have an effect on lipid and clearly, after we announce our top line results there may be an opportunity there to take advantage of some of these sub indications and kind of blow them out if you will. So, I’ll be able to comment much more on that at the time we report our top line results because then it will make more sense.
Eric Schmidt – Cowen & Company
And just to be clear, on this self imposed quite period, management hasn’t seen any unblinded data, it’s just that you expect that data to be coming shortly?
Mitchell S. Steiner, M.D.
This is our position; our position is that we have shared with everybody that we’re going to be getting the data in a later part of this quarter. We’re on track to do that. What’s awkward is that people are trying to read into everything we do as an indication that we know something that we don’t know. So, the best way to handle that is that management has said, ?You know what, to be fair and to be considerate, our position is to stay in this quite period because the latter part of this quarter, we’re getting into the latter part of this quarter.? So, as you know we’ve given good guidance in the past and we’re going to continue to execute as we have in the past. So, to that end it’s fair to say that the quite period is self imposed. The quite period was not imposed because management is sitting on data and that we’ve seen something. It’s being imposed because of the imminent nature of receiving the data and trying to make conclusions out of that.
- To read the full transcript on Seeking Alpha, click here »
